Squamous cell carcinoma, adenosquamous carcinoma, basal cell carcinoma
Conditions
Interventions
Use Epicil to prevent the onset of oral mucositis during neoadjuvant chemotherapy with DFP
Sponsors
Momota Yukihiro
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients who are histologically diagnosed as squamous cell carcinoma, adenosquamous carcinoma, or basal cell carcinoma by endoscopic biopsy of the primary esophageal lesion 2.Patients whose treatment policy in esophageal surgery is preoperative chemotherapy with DFP and surgery 3.Patients whose Performance status (PS) is 0, 1 or 2 according to ECOG criteria 4.Patients who have written consent to participate in the study
Exclusion criteria
Exclusion criteria: 1.Patients with cancer lesions in the oral cavity 2.Patients with obvious wounds in the oral cavity other than oral mucositis 3.Patients known to be allergic to the components of Epicil 4.Patients participating in other clinical trials or clinical studies 5.Female patients who are breastfeeding, pregnant, or may become pregnant 6.In addition, patients who find it difficult to carry out this study at the discretion of the researcher
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity assessment of oral mucositis by CTCAC v3.0 | — |
Secondary
| Measure | Time frame |
|---|---|
| (1) Severity evaluation of oral mucositis by CTCAE v4.0 (2) Evaluation of pain by Numerical Rating Scale (NRS) (3) Incidence of oral mucositis | — |
Contacts
Public ContactTAKANO HIDEYUKI
Tokushima University Hospital
Outcome results
None listed